COVID-19: Considerations and Implications for Digital Biomarkers in Clinical Trials
- Koneksa Health
- Apr 2, 2020
- 2 min read
Updated: Jul 19
The use of remote digital measures — sensors, wearables, and other non-invasive remote measurement tools — is a key component of how researchers will respond to the COVID-19 pandemic. The FDA has issued two guidance documents in the space of one week — an unprecedented regulatory response. Adopting some elements of the FDA recommendations — remote monitoring, virtual labs, at-home assessments — will require technology tools already designed as fit-for-purpose clinical trial tools. The agency has detailed non-invasive remote monitoring tools that sponsor companies should be considering, such as devices for remote respiratory assessments, temperature monitoring, and pulse oximetry measurements.
The decision-making process for implementing a digital measure, as either an endpoint or a monitoring tool, into a clinical trial is complex. Issues regarding device selection, patient compliance, and clinical utility should all be considered. Designing a statistical analysis plan to convert continuous monitoring data and big data sets into usable clinical information requires careful planning and an understanding of how wearable data is translated into clinically meaningful information.
In this webinar, the speakers will review:
The current regulatory environment, including guidance documents issued by the FDA and EMA on preserving the integrity of clinical trials while balancing the safety concerns associated with social distancing and the COVID pandemic
Considerations when adding digital measures to your clinical trial
Evaluation criteria when choosing a wearable or sensor to use in your trial
What to consider for remote patient monitoring in your study
Speakers:
John Wagner, MD, PhD, Partner, Foresite Capital
Elena Izmailova, CSO, Koneksa Health
Andy Coravos, Digital Medicine Society and CEO of Elektra Labs
References:
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic
FDA Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring During the Coronavirus Disease-2019 (COVID-19) Public Health Emergency
EMA Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic
UK GLPMA Guidance for Good Laboratory Practice (GLP) facilities in relation to coronavirus (COVID-19)
I was diagnosed with Parkinson’s disease four years ago. For over two years, I relied on prescription medications and therapies, but unfortunately, the symptoms continued to worsen. My mobility declined, tremors increased, and I experienced growing fatigue and discomfort that affected my daily life. Last year, out of desperation and hope, I decided to try an herbal treatment program from NaturePath Herbal Clinic. Honestly, I was skeptical at first, but within a few months of starting the treatment, I began to notice real changes. My energy improved, the discomfort eased, and I felt stronger and more capable in my daily life. Incredibly, I also regained much of my stamina, balance, and confidence. It’s been a life-changing experience I feel more…